Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin.

The evaluation of peptide receptors in man is needed not only to discover the physiological target tissues of a given peptide but also to identify diseases with a sufficient receptor overexpression for diagnostic or therapeutic interventions. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) receptors have been evaluated in human tumors and in their tissues of origin using in vitro receptor autoradiography with 125I-VIP or 125I-acetyl-PACAP-27 in tissue sections. The VIP/PACAP receptor subtypes VPAC1, VPAC2, and PAC1 were evaluated in these tissues by determining the rank order of potencies of VIP and PACAP as well as VPAC1- and VPAC2-selective analogues. The VIP/PACAP receptors expressed in the great majority of the most frequently occurring human tumors, including breast (100% receptor incidence), prostate (100%), pancreas (65%), lung (58%), colon (96%), stomach (54%), liver (49%), and urinary bladder (100%) carcinomas as well as lymphomas (58%) and meningiomas (100%), are predominantly of the VPAC1 type. Their cells or tissues of origin, i.e., hepatocytes, breast lobules and ducts, urothelium, prostate glands, pancreatic ducts, lung acini, gastrointestinal mucosa, and lymphocytes, also predominantly express VPAC1. Leiomyomas predominantly express VPAC2 receptors, whereas paragangliomas, pheochromocytomas, and endometrial carcinomas preferentially express PAC1 receptors. Conversely, VPAC2 receptors are found mainly in smooth muscle (i.e., stomach), in vessels, and in stroma (e.g., of the prostate), whereas PAC1 receptors are present in the adrenal medulla and in some uterine glands. Whereas the very wide distribution of VIP/PACAP receptors in the normal human body is indicative of a key role of these peptides in human physiology, the high VIP/PACAP receptor expression in tumors may represent the molecular basis for clinical applications of VIP/PACAP such as in vivo scintigraphy and radiotherapy of tumors as well as VIP/PACAP analogue treatment for tumor growth inhibition.

[1]  P. Robberecht,et al.  Development of High Affinity Selective VIP1 Receptor Agonists , 1997, Peptides.

[2]  I. Tatsuno,et al.  Maxadilan Is a Specific Agonist and Its Deleted Peptide (M65) Is a Specific Antagonist for PACAP Type 1 Receptor , 1998, Annals of the New York Academy of Sciences.

[3]  P. Neuhaus,et al.  Regulatory peptide receptors in human hepatocellular carcinomas , 1999, Gut.

[4]  J. Laissue,et al.  Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. , 1996, Cancer research.

[5]  J. Mueller‐Brand,et al.  Yttrium-90-labelled somatostatin-analogue for cancer treatment , 1998, The Lancet.

[6]  P. Robberecht,et al.  The Long-Acting Vasoactive Intestinal Polypeptide Agonist RO 25-1553 Is Highly Selective of the VIP2 Receptor Subclass , 1997, Peptides.

[7]  F. Paraf,et al.  Pituitary adenylate cyclase activating peptide and its receptors are expressed in human neuroblastomas , 1996, Journal of cellular physiology.

[8]  G. Greenberg,et al.  High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes , 1990, Journal of Neuroimmunology.

[9]  J C Reubi,et al.  In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  S. Jiang,et al.  Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. , 1997, Cancer research.

[11]  C. Raftopoulos,et al.  Receptors for pituitary adenylate cyclase activating peptides in human pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.

[12]  T. Moody,et al.  Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. , 1996, Cancer Research.

[13]  T. Moody,et al.  A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Laissue,et al.  Localization of receptors for vasoactive intestinal peptide, somatostatin, and substance P in distinct compartments of human lymphoid organs. , 1998, Blood.

[15]  S. Rawlings,et al.  International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. , 1998, Pharmacological reviews.

[16]  J. Laissue,et al.  Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro‐intestinal adenocarcinoma samples: Where are they really located? , 1999, International journal of cancer.

[17]  L. Mazzucchelli,et al.  Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. , 1994, Gastroenterology.

[18]  R. Valkema,et al.  Somatostatin receptor: scintigraphy and radionuclide therapy. , 1996, Digestion.

[19]  R. Hauger,et al.  N‐Terminal Splice Variants of the Type I PACAP Receptor: Isolation, Characterization and Ligand Binding/Selectivity Determinants , 1999, Journal of neuroendocrinology.

[20]  W. Scheithauer,et al.  Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. , 1994, The New England journal of medicine.

[21]  T. Moody,et al.  Pituitary adenylate cyclase activating peptide receptors regulate the growth of non-small cell lung cancer cells. , 1995, Cancer research.

[22]  S. Said,et al.  Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  B. Scheithauer,et al.  Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. , 1998, The American journal of pathology.

[24]  H. Hashimoto,et al.  Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. , 1997, Molecular pharmacology.

[25]  P. Hof,et al.  Autoradiographic mapping of [mono[125I]iodo-Tyr10, MetO17]vasoactive intestinal peptide binding sites in the rat brain , 1987, Neuroscience.

[26]  J. Charboneau,et al.  Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. , 1990, Cancer research.

[27]  J. Brotchi,et al.  Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors , 1994, Peptides.